NCT04150029 - A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

October 25, 2024

Study Completion Date

October 25, 2024

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

MBG453

Solution for intravenous infusion

DRUG

Venetoclax

Tablet for oral administration

DRUG

Azacitidine

Solution for subcutaneous injection or intravenous infusion

Trial Locations (28)

3168

Novartis Investigative Site, Clayton

10017

Memorial Sloan Kettering, New York

10021

Weill Cornell Medicine NY-Presb, New York

13353

Novartis Investigative Site, Berlin

20162

Novartis Investigative Site, Milan

27710

Duke Univ Medical Center, Durham

28009

Novartis Investigative Site, Madrid

28204

Levine Cancer Insitute Carolinas Healthcare System, Charlotte

31059

Novartis Investigative Site, Toulouse

35294

25Uni of Alabama at Birmingham, Birmingham

37404

Chattanooga Onc And Hem Assoc PC, Chattanooga

52242

Uni Of Iowa Hospitals And Clinics, Iowa City

55905

Mayo Clinic Rochester, Rochester

75475

Novartis Investigative Site, Paris

77030

MD Anderson Cancer Center University of Texas, Houston

83301

Novartis Investigative Site, Kaohsiung City

06520

Yale University School Of Medicine, New Haven

02215

Dana Farber Cancer Institute, Boston

84112 0550

Huntsman Cancer Institute Univ of Utah, Salt Lake City

V5Z 1M9

Novartis Investigative Site, Vancouver

M5G 2M9

Novartis Investigative Site, Toronto

H3T 1E2

Novartis Investigative Site, Montreal

04103

Novartis Investigative Site, Leipzig

00133

Novartis Investigative Site, Roma

960 1295

Novartis Investigative Site, Fukushima

990 9585

Novartis Investigative Site, Yamagata

06591

Novartis Investigative Site, Seoul

08036

Novartis Investigative Site, Barcelona